Circadian rhythm-based cancer therapy in randomised clinical trials

References

• Dierickx P, Van Laake LW, Geijsen N. Circadian clocks: from stem cells to tissue homeostasis and regeneration. EMBO Rep. 2018;19(1):18–28. doi: 10.15252/embr.201745130
   PubMed Web of Science ®Google Scholar
• De A, Beligala DH, Sharma VP, et al. Cancer stem cell generation during epithelial-mesenchymal transition is temporally gated by intrinsic circadian clocks. Clin Exp Metastasis. 2020;37(5):617–635. doi: 10.1007/s10585-020-10051-1
   PubMed Web of Science ®Google Scholar
• Chan S, Rowbottom L, McDonald R, et al. Does the time of radiotherapy affect treatment outcomes? A review of the literature. Clin Oncol (R Coll Radiol). 2017;29(4):231–238. doi: 10.1016/j.clon.2016.12.005
   PubMed Web of Science ®Google Scholar
• Matsuo T, Yamaguchi S, Mitsui S, et al. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302(5643):255–9. doi: 10.1126/science.1086271
   PubMed Web of Science ®Google Scholar
• Ashok Kumar PV, Dakup PP, Sarkar S, et al. It’s about time: advances in understanding the circadian regulation of DNA damage and repair in carcinogenesis and cancer treatment outcomes. Yale J Biol Med. 2019;92(2):305–316.
   PubMed Web of Science ®Google Scholar
• Lévi F, Focan C, Karaboué A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007;59(9–10):1015–35. doi: 10.1016/j.addr.2006.11.001
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang J, Zhang X, et al. New insights into cancer chronotherapies. Front Pharmacol. 2021;12:741295. doi: 10.3389/fphar.2021.741295
   PubMed Web of Science ®Google Scholar
• Marcu LG. Developments on tumour site-specific chrono-oncology towards personalised treatment. Crit Rev Oncol/Hematol. 2022;179:103803.
   PubMed Web of Science ®Google Scholar
• Rivard GE, Infante-Rivard C, Hoyoux C, et al. Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening. Lancet. 1985;2(8467):1264–1266. doi: 10.1016/S0140-6736(85)91551-X
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Glomstein A, Kristinsson J, et al. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1997;19(2):102–109. doi: 10.1097/00043426-199703000-00002
   PubMed Web of Science ®Google Scholar
• Rivard GE, Infante-Rivard C, Dresse MF, et al. Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. Chronobiol Int. 1993;10(3):201–4. doi: 10.3109/07420529309073888
   PubMed Web of Science ®Google Scholar
• Clemmensen KK, Christensen RH, Shabaneh DN, et al. Nordic Society of Pediatric Hematology, oncology (NOPHO) the circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol. Pediatr Blood Cancer. 2014;61(4):653–658. doi: 10.1002/pbc.24867
   PubMed Web of Science ®Google Scholar
• Kim DW, Byun JM, Lee JO, et al. Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma. JCI Insight. 2023;8(2):e164767. doi: 10.1172/jci.insight.164767
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol. 1999;154(2):613–622. doi: 10.1016/S0002-9440(10)65306-0
   PubMed Web of Science ®Google Scholar
• Bjarnason GA, Mackenzie RG, Nabid A, et al. Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the national cancer Institute of Canada clinical trials group (HN3). Int J Radiat Oncol Biol Phys. 2009;73(1):166–72. doi: 10.1016/j.ijrobp.2008.07.009
   PubMed Web of Science ®Google Scholar
• Goyal M, Shukla P, Gupta D, et al. Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. Int J Radiat Biol. 2009;85(6):504–9. doi: 10.1080/09553000902883802
   PubMed Web of Science ®Google Scholar
• Zhang PX, Jin F, Li ZL, et al. A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy. Chronobiol Int. 2018;35(2):240–248. doi: 10.1080/07420528.2017.1397684
   PubMed Web of Science ®Google Scholar
• Brolese EK, Cihoric N, Bojaxhiu B, et al. The impact of delivery daytime and seasonality of radiotherapy for head and neck cancer on toxicity burden. Radiother Oncol. 2021;158:162–166. doi: 10.1016/j.radonc.2021.02.039
   PubMed Web of Science ®Google Scholar
• Kabolizadeh P, Wegner R, Bernard M, et al. The effect of treatment time on outcome in non-small cell lung cancer brain metastases treated with stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2011;81(2):S301. doi: 10.1016/j.ijrobp.2011.06.1784
   Google Scholar
• Rahn DA, Ray DK, Schlesinger DJ, et al. Gamma Knife Radiosurgery for brain metastasis of nonsmall cell lung cancer: is there a difference in outcome between morning and afternoon treatment? Cancer. 2011;117(2):414–420. doi: 10.1002/cncr.25423
   PubMed Web of Science ®Google Scholar
• Badiyan SN, Ferraro DJ, Yaddanapudi S, et al. EP-1293 IMPACT of TIME of DAY of GAMMA KNIFE RADIOSURGERY on SURVIVAL for NON-SMALL CELL LUNG CANCER BRAIN METASTASES. Radiother Oncol. 2012;103:S491–2. doi: 10.1016/S0167-8140(12)71626-2
   Google Scholar
• Badiyan SN, Ferraro DJ, Yaddanapudi S, et al. Impact of time of day on outcomes after stereotactic radiosurgery for non-small cell lung cancer brain metastases. Cancer. 2013;119(19):3563–3569. doi: 10.1002/cncr.28237
   PubMed Web of Science ®Google Scholar
• Karaboué A, Collon T, Pavese I, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a Pilot study in patients with metastatic non-small-cell lung cancer. Cancers (Basel). 2022;14(4):896. doi: 10.3390/cancers14040896
   PubMed Web of Science ®Google Scholar
• Li J, Chen R, Ji M, et al. Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis. Cancer Chemother Pharmacol. 2015;76(3):651–5. doi: 10.1007/s00280-015-2804-x
   PubMed Web of Science ®Google Scholar
• Focan C, Kreutz F, Longrée L, et al. Interest of chronotherapy in multidisciplinary management of oesophageal and gastric cancers. Pathol Biol (Paris). 2007;55(3–4):181–185. doi: 10.1016/j.patbio.2006.12.002
   PubMedGoogle Scholar
• Chen R, Li J, Hu WW, et al. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program. Cancer Chemother Pharmacol. 2013;72(5):1111–23. doi: 10.1007/s00280-013-2288-5
   PubMed Web of Science ®Google Scholar
• Lévi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86(21):1608–1617. doi: 10.1093/jnci/86.21.1608
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, et al. European organisation for research and treatment of cancer chronotherapy group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European organisation for research and treatment of cancer chronotherapy group. J Clin Oncol. 2006;24(22):3562–3569. doi: 10.1200/JCO.2006.06.1440
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Dugué PA, Innominato PF, et al. ARTBC International chronotherapy group sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol. 2012;23(12):3110–3116. doi: 10.1093/annonc/mds148
   PubMed Web of Science ®Google Scholar
• ARTBC International Chronotherapy Group, Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo S, Carvalho C Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011;28(7):586–600.
   PubMed Web of Science ®Google Scholar
• Innominato PF, Ballesta A, Huang Q, et al. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: randomized multicenter EORTC 05011 trial. Cancer Med. 2020;9(12):4148–4159. doi: 10.1002/cam4.3056
   PubMed Web of Science ®Google Scholar
• Levi F, Ballesta A, Karaboue A, et al. Optimizing FOLFIRINOX tolerability in patients with colorectal cancer through dosing irinotecan in the morning for men and in the afternoon for women. J Clin Oncol. 2020;38(suppl 4):120. doi: 10.1200/JCO.2020.38.4_suppl.120
   Web of Science ®Google Scholar
• Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer. 2005;103(6):1165–71. doi: 10.1002/cncr.20878
   PubMed Web of Science ®Google Scholar
• Marcu LG. Gender and sex-related differences in normal tissue effects induced by platinum compounds. Pharmaceuticals (Basel). 2022;15(2):255. doi: 10.3390/ph15020255
   PubMedGoogle Scholar
• Innominato PF, Giacchetti S, Bjarnason GA, et al. Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer. 2012;131(11):2684–92. doi: 10.1002/ijc.27574
   PubMed Web of Science ®Google Scholar
• International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group; Innominato PF, Giacchetti S, Moreau T, et al. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer. 2013;119(14):2564–73.
   PubMed Web of Science ®Google Scholar
• Gholam D, Giacchetti S, Brézault-Bonnet C, et al. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncology. 2006;11(10):1072–80. doi: 10.1634/theoncologist.11-10-1072
   Google Scholar
• Shukla P, Gupta D, Bisht SS, et al. Circadian variation in radiation-induced intestinal mucositis in patients with cervical carcinoma. Cancer. 2010;116(8):2031–5. doi: 10.1002/cncr.24867
   PubMed Web of Science ®Google Scholar
• Buchi KN, Moore JG, Hrushesky WJ, et al. Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology. 1991;101(2):410–415. doi: 10.1016/0016-5085(91)90019-H
   PubMed Web of Science ®Google Scholar
• Chang L, Li L, Li W, et al. Research on radiotherapy at different times of the day for inoperable cervical cancer. Int J Clin Pharmacol Ther. 2016;54(11):856–864. doi: 10.5414/CP202654
   PubMed Web of Science ®Google Scholar
• Beltran-Bless AA, Vandermeer L, Ibrahim MFK, et al. Does the time of day at which endocrine therapy is taken affect breast cancer patient outcomes? Curr Oncol. 2021;28(4):2523–2528. doi: 10.3390/curroncol28040229
   PubMed Web of Science ®Google Scholar
• [cited 2023 oct 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT04864405
   Google Scholar
• [cited 2023 oct 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02781792
   Google Scholar
• [cited 2023 oct 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT04735939
   Google Scholar
• European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group; Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
   PubMed Web of Science ®Google Scholar
• Alves ALV, Gomes INF, Carloni AC, et al. Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Res Ther. 2021;12(1):206. doi: 10.1186/s13287-021-02231-x
   PubMed Web of Science ®Google Scholar
• Beier D, Rohrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008;68(14):5706–15. doi: 10.1158/0008-5472.CAN-07-6878
   PubMed Web of Science ®Google Scholar
• Damato AR, Luo J, Katumba RGN, et al. Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study. Neurooncol Adv. 2021;3(1):vdab041. doi: 10.1093/noajnl/vdab041
   PubMedGoogle Scholar
• Damato AR, Katumba RGN, Luo J, et al. A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Neurooncol Pract. 2022;9(3):193–200. doi: 10.1093/nop/npac003
   PubMed Web of Science ®Google Scholar
• Qian DC, Kleber T, Brammer B, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22(12):1777–1786. doi: 10.1016/S1470-2045(21)00546-5
   PubMedGoogle Scholar
• De Courcy L, Bezak E, Marcu LG. Gender-dependent radiotherapy: the next step in personalised medicine? Crit Rev Oncol Hematol. 2020;147:102881. doi: 10.1016/j.critrevonc.2020.102881
   PubMed Web of Science ®Google Scholar
• Mormont MC, Lévi F. Circadian-system alterations during cancer processes: a review. Int J Cancer. 1997;70(2):241–247. doi: 10.1002/(SICI)1097-0215(19970117)70:2<241:AID-IJC16>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Matsunaga N, Ogino T, Hara Y, et al. Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Res. 2018;78(13):3698–3708. doi: 10.1158/0008-5472.CAN-17-4034
   PubMed Web of Science ®Google Scholar
• Malik A, Nalluri S, De A, et al. The relevance of circadian clocks to stem cell differentiation and cancer progression. Neurosci. 2022;3(2):146–165. doi: 10.3390/neurosci3020012
   Google Scholar
• Bermúdez-Guzmán L, Blanco-Saborío A, Ramírez-Zamora J, et al. The time for chronotherapy in radiation oncology. Front Oncol. 2021;11:687672. doi: 10.3389/fonc.2021.687672
   PubMed Web of Science ®Google Scholar
• Cederroth CR, Albrecht U, Bass J, et al. Medicine in the fourth dimension. Cell Metab. 2019;30(2):238–250. doi: 10.1016/j.cmet.2019.06.019
   PubMed Web of Science ®Google Scholar